28 Dec
2022
12:59 E.S.T.

Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities

Read more

22 Dec
2022
16:30 E.S.T.

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Read more

13 Dec
2022
07:30 E.S.T.

Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Read more

01 Dec
2022
16:30 E.S.T.

Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

Read more

10 Nov
2022
09:05 E.S.T.

Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022

Read more

10 Nov
2022
02:30 E.S.T.

Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

Read more

03 Nov
2022
16:05 E.S.T.

Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022

Read more

03 Nov
2022
13:43 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022

Read more

27 Oct
2022
16:30 E.S.T.

Cellectis to Report Third Quarter 2022 Financial Results

Read more

11 Oct
2022
16:30 E.S.T.

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Read more